<DOC>
	<DOCNO>NCT01060423</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy Irinotecan Beads combination intravenous cetuximab versus intravenous irinotecan combination intravenous cetuximab treatment patient unresectable liver metastasis colorectal cancer . Secondary objective safety tolerability hepatic chemoembolization question addition aprepitant standard antiemetic prophylaxis patient treat hepatic chemoembolization safe reduce rate acute delay nausea emesis .</brief_summary>
	<brief_title>TACE With Irinotecan Drug-eluting Beads Intravenous ( IV ) Cetuximab Refractory Colorectal Cancer</brief_title>
	<detailed_description>About half patient newly diagnose colorectal cancer develop metastatic disease , however , spite significant progress therapeutical strategy metastatic disease , virtually patient eventually succumb illness . Based prior clinical data good rationale expectation combination systemic chemotherapy arterial chemoembolization drug elute bead may effective set patient unresectable chemorefractory liver metastasis . The aim study therefore ass whether combination Irinotecan elute bead intravenous cetuximab safe effective treatment patient unresectable liver metastasis refractory colorectal cancer result prolongation disease control compare standard systemic treatment intravenous irinotecan intravenous cetuximab . In patient group , intravenous irinotecan plus intravenous cetuximab may represent `` standard care '' , previously describe activity . The patient group define term pretreatment , scientific question whether way irinotecan administration elute bead feasible somehow beneficial .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Patients confirm diagnosis stage IV ( UICC ) colorectal cancer unresectable liver metastasis ( primary tumour may present ) kras wildtype tumour 2 . Patients treat show refractory 5FU ( Capecitabine allow ) /oxaliplatin and/or 5FU/irinotecan . Prior therapy VEGFinhibitors ( e.g bevacizumab ) allow 3 . Patients least one measurable liver metastasis , size &gt; 1cm ( RECIST criterion ) 4 . Patients liver liver dominant disease ( define ≥ 50 % tumour burden confine liver ) 5 . Patients portal vein interfere transarterial chemoembolization ( e.g . thrombosis ) judge investigator 6 . ECOG Performance status ≤ 2 7 . Life expectancy &gt; 3 month 8 . Age ≥ 18 year . 9 . At least 4 week since last administration last chemotherapy and/or radiotherapy ( bone metastasis may allow ) 10 . Patients receive VEGFinhibition ( e.g . bevacizumab ) prior therapy eligible stop since 46 week randomization 11 . Haematologic function : ANC ≥ 1.5 x 109/L , platelet ≥ 75 x109/L 12 . INR &lt; 1.5 ( patient therapeutic anticoagulant eligible ) 13 . Adequate liver function measure serum transaminase ( AST &amp; ALT ) ≤ 3 x ULN total bilirubin ≤ 1.5 x ULN 14 . Adequate renal function : Serum creatinine ≤ 1.5 x ULN 15 . Normal level serum magnesium 16 . Women child bear potential fertile men require use effective contraception ( negative serum βHCG woman childbearing age 17 . Signed , write informed consent 1 . Presence CNS metastases 2 . Contraindications irinotecan therapy ( Chronic inflammatory bowel disease and/or bowel obstruction , history severe hypersensitivity reaction irinotecan hydrochloride trihydrate ) 3 . Active bacterial , viral fungal infection within 72 hour study entry 4 . Women pregnant breast feed 5 . Allergy contrast medium 6 . Presence another concurrent malignancy . Prior malignancy last 5 year except adequately treat basal squamous cell skin cancer carcinoma situ cervix 7 . Any contraindication hepatic embolisation procedure : Large shunt determine investigator ( pretesting lung perfusion scan require ) Severe atheromatosis Hepatofugal blood flow 8 . Other significant medical surgical condition , medication treatment , would place patient undue risk , would preclude safe use chemoembolization would interfere study participation 9 . Known hypersensitivity contraindication drug use trial ( eg : cetuximab , 5HT3 receptor antagonist , dexamethasone , component aprepitant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>colorectal</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>KRAS wildtype</keyword>
	<keyword>chemoembolization</keyword>
	<keyword>irinotecan elute bead</keyword>
</DOC>